Abingworth Bioventures VI LP

About Abingworth Bioventures VI LP

Abingworth Bioventures VI LP is a life sciences investment vehicle associated with the Abingworth Bioventures VI fund. In the context of MEDIAN Technologies, it is not an operating executive role in the usual sense, but rather a significant institutional shareholder and long-term financial backer of the company. MEDIAN Technologies’ recent financial reports show that Abingworth Bioventures VI LP held approximately 5.17% of the share capital as of December 31, 2024, after holding 5.19% as of June 30, 2024, making it one of the company’s principal shareholders on Euronext Growth Paris. The Abingworth Bioventures VI fund was launched by Abingworth, an international investment group focused on life sciences and healthcare. Announced in 2014, ABV VI was designed to invest across a broad range of company stages, including private venture rounds, growth investments, and listed public equity positions, with a clear emphasis on innovative healthcare companies. Abingworth has specifically presented its involvement in MEDIAN Technologies as backing a next-generation medical imaging company with international potential in oncology, cancer detection, and treatment monitoring. From a corporate governance perspective, Abingworth Bioventures VI LP signals a strategic alignment with MEDIAN Technologies’ long-term development needs. MEDIAN is a French listed medtech company founded in 2002, developing software solutions and imaging services for oncology. Its business model is capital-intensive and innovation-driven, requiring recurring financing and a strong shareholder base to support product development, commercialization, and market expansion. As a specialized institutional investor, Abingworth brings sector expertise, credibility in healthcare investing, and experience supporting growth-stage companies through value-creation phases. For SEO purposes, Abingworth Bioventures VI LP should therefore be described primarily as a key shareholder of MEDIAN Technologies rather than as an executive officer. Its role is that of a specialized investor supporting financing, governance stability, and strategic growth in a listed medical technology company. This position enhances MEDIAN’s market visibility and underscores Abingworth’s focus on globally scalable healthcare innovation.